Elanco Animal Health Incorporated
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jeffrey N. Simmons
- Full Time Employees
- 9,650
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 450 Elanco Circle Indianapolis IN United States of America 46221
- IPO Date
- Sep 20, 2018
- CIK
- 0001739104
- Website
- elanco.com
- Similar Companies
- Business
- Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health that develops, manufactures, and markets innovative products and services to prevent and treat diseases in farm animals and pets. The company offers a comprehensive portfolio including parasiticides such as Credelio Quattro, Zenrelia, Advantage Family, and Seresto for pets; productivity enhancers like Experior and AdTab for cattle; vaccines, antibiotics, and feed additives for poultry and swine; and knowledge services providing data-driven insights to veterinarians, farmers, and pet owners worldwide. Elanco operates in over 100 countries with a focus on pet health and livestock sustainability segments, targeting veterinarians, farmers, pet owners, and food producers. Founded in 1954 as a division of Eli Lilly and Company and headquartered in Indianapolis, Indiana, Elanco spun off as an independent public company in 2018 and maintains manufacturing, research, and commercial operations globally. Recent strategic changes include the completed divestiture of its aqua business to Merck Animal Health for $1.3 billion in July 2024, enabling focus on core pet and farm animal growth areas; refinancing of a $2.1 billion Term Loan B facility in 2025 to extend maturities to 2032 and reduce interest costs; monetization of certain lotilaner U.S. royalties for $295 million in May 2025; and the opening of a new global headquarters in downtown Indianapolis. In third quarter 2025 results, Elanco reported organic constant currency revenue growth of 9%, driven by strong performances from Credelio Quattro (reaching $100 million in net sales within eight months), Zenrelia (global sales nearly doubling quarter-over-quarter with launches in the EU, Great Britain, and Australia), Experior (up 70% year-over-year), and AdTab (up over 25% year-over-year), while raising full-year 2025 guidance for revenue, innovation revenue, adjusted EBITDA, and adjusted EPS alongside an improved year-end net leverage ratio target of 3.7x to 3.8x.
Company News
Canada Pension Plan Investment Board Purchases New Holdings in Elanco Animal Health Incorporated $ELAN
348,043 Shares in Elanco Animal Health Incorporated $ELAN Bought by Corient Private Wealth LP
Corient Private Wealth LP Acquires 195,312 Shares of Elanco Animal Health Incorporated $ELAN
Elanco Animal Health Incorporated $ELAN Shares Sold by Algert Global LLC
Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility
Elanco Animal Health: New Products To Support Growth
Director's Confidence Visible as Elanco Leader Buys 10,000 Shares
Netflix, Eli Lilly, Elanco Animal Health And More Stock On CNBC's ‘Final Trades'
Elanco: Innovation Is Turning A Leveraged Portfolio Into A Share-Taking Platform
Elanco Animal Health Q2 Earnings Call Highlights
Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livest
Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species
Amundi Has $2.35 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN
Elanco Animal Health Inc (ELAN) Shares Fall 7.7% -- What GF Score of 66 Tells Investors
Elanco CEO on Boosted Forecast, Surge in Tick Bites
ADUS vs. ELAN: Which Stock Is the Better Value Option?
Elanco Animal Health Incorporated (ELAN) Q2 2026 Earnings Call Transcript
Elanco Sees Strong Pet Health Momentum, Bets on Innovative Products
Elanco Animal Health (ELAN) Reports Q2 Earnings: What Key Metrics Have to Say
Elanco Animal Health Incorporated (ELAN) Q2 Earnings and Revenues Beat Estimates